Safety is demonstrated by concurrent use of atogepant and ubergepant for both preventive and acute migraine.

Published Date: 18 Apr 2024

During the course of a 12-week trial, the combination of atogepant and ubrogepant produced few adverse events and was safe and well-tolerated.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Nuclear missile workers are contracting cancer: They blame the bases

2.

Mixed Results With Cyclophosphamide in Mismatched Unrelated Stem Cell Transplants

3.

New analysis helps discern benign from malignant thyroid growths

4.

MCh in Gynecologic Oncology: Admission, Medical School, Fees, Qualifications Information

5.

Even a few mutated cells can significantly impact how blood cancers develop, study finds


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot